Adrian H. C. Koh
Adrian H. C. Koh has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Won Ki Lee
Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea
2 shared publicationsAnantharam Giridhar
1 shared publication- Annabelle Ayame Okada
Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan
1 shared publication - Antonia Maria Joussen
Department of Ophthalmology, Charité—Universitätsmedizin Berlin, 12203 Berlin, Germany
1 shared publication Chi-Chun Lai
Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan, Taiwan
1 shared publication- Chui Ming Gemmy Cheung
Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore
1 shared publication
Latest Publications
- Open Access
- 16 December 2020
- Published by Wolters Kluwer Health in Retina
- Vol. 41 (4) , 671-678
MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
Purpose: This article aims to review current evidence on the development, diagnosis, and management of retinal pigment epithelium (RPE) tear during anti–vascular endothelial growth factor (VEGF) therapy. Methods: Literature searches were performed using MEDLINE/PubMed databases (cut-off date: August 2019). Results: Three key recommendations were made based on existing literature and clinical experience: 1) Multimodal imaging with color fundus photography, optical coherence tomography, near-infrared reflectance imaging, fundus autofluorescence imaging, optical coherence tomography-angiography, and/or fluorescein angiography are recommended to diagnose RPE tear and assess risk factors. Retinal pigment epithelium tears can be graded by size and foveal involvement. 2) Patients at high risk of developing RPE tear should be monitored after each anti-VEGF injection. If risk factors worsen, it is not yet definitively known whether anti-VEGF administration should be more frequent, or alternatively stopped in such patients. Prospective research into high-risk characteristics is needed. 3) After RPE tear develops, anti-VEGF treatment should be continued in patients with active disease (as indicated by presence of intraretinal or subretinal fluid), although cessation of therapy should be considered in eyes with multilobular tears. Conclusion: Although evidence to support the assumption that anti-VEGF treatment contributes to development of RPE tear is not definitive, some data suggest this link.
- 16 December 2020
- Published by Wolters Kluwer Health in Retina
- Vol. 41 (4) , 671-678
Open AccessMANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
Purpose: This article aims to review current evidence on the development, diagnosis, and management of retinal pigment epithelium (RPE) tear during anti–vascular endothelial growth factor (VEGF) therapy. Methods: Literature searches were performed using MEDLINE/PubMed databases (cut-off date: August 2019). Results: Three key recommendations were made based on existing literature and clinical experience: 1) Multimodal imaging with color fundus photography, optical coherence tomography, near-infrared reflectance imaging, fundus autofluorescence imaging, optical coherence tomography-angiography, and/or fluorescein angiography are recommended to diagnose RPE tear and assess risk factors. Retinal pigment epithelium tears can be graded by size and foveal involvement. 2) Patients at high risk of developing RPE tear should be monitored after each anti-VEGF injection. If risk factors worsen, it is not yet definitively known whether anti-VEGF administration should be more frequent, or alternatively stopped in such patients. Prospective research into high-risk characteristics is needed. 3) After RPE tear develops, anti-VEGF treatment should be continued in patients with active disease (as indicated by presence of intraretinal or subretinal fluid), although cessation of therapy should be considered in eyes with multilobular tears. Conclusion: Although evidence to support the assumption that anti-VEGF treatment contributes to development of RPE tear is not definitive, some data suggest this link.
- Open Access
- 1 August 2020
- Published by Wolters Kluwer Health in Retina
- Vol. 40 (8) , 1529-1539
REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY
Purpose: To evaluate the real-world effectiveness and safety of intravitreal ranibizumab 0.5 mg in treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV). Methods: Assessment of neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study. Outcome measures were visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events. Results: At baseline, 572 and 5,644 patients were diagnosed with and without PCV, respectively. The mean visual acuity gain from baseline at Month 12 in the PCV and non-PCV groups was +5.0 and +3.0 letters, respectively; these gains were achieved with a mean of 4.4 and 5.1 ranibizumab injections. Eighty percent of PCV patients and 72.2% of non-PCV patients who had baseline visual acuity ≥73 letters maintained this level of vision at Month 12; 20.6% and 17.9% of patients with baseline visual acuity <73 letters achieved visual acuity ≥73 letters in these groups. Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group. The rate of serious ocular adverse events was 0.7% (PCV group) and 0.9% (non-PCV group). Conclusion: LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV.
- 1 August 2020
- Published by Wolters Kluwer Health in Retina
- Vol. 40 (8) , 1529-1539
Open AccessREAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY
Purpose: To evaluate the real-world effectiveness and safety of intravitreal ranibizumab 0.5 mg in treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV). Methods: Assessment of neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study. Outcome measures were visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events. Results: At baseline, 572 and 5,644 patients were diagnosed with and without PCV, respectively. The mean visual acuity gain from baseline at Month 12 in the PCV and non-PCV groups was +5.0 and +3.0 letters, respectively; these gains were achieved with a mean of 4.4 and 5.1 ranibizumab injections. Eighty percent of PCV patients and 72.2% of non-PCV patients who had baseline visual acuity ≥73 letters maintained this level of vision at Month 12; 20.6% and 17.9% of patients with baseline visual acuity <73 letters achieved visual acuity ≥73 letters in these groups. Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group. The rate of serious ocular adverse events was 0.7% (PCV group) and 0.9% (non-PCV group). Conclusion: LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV.
- 13 June 2020
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 258 (10) , 2091-2094
What COVID-19 has taught us: lessons from around the globe
- 13 June 2020
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 258 (10) , 2091-2094
What COVID-19 has taught us: lessons from around the globe
- Open Access
- 1 January 2017
- Published by Asia Pacific Academy of Ophthalmology in Asia-Pacific Journal of Ophthalmology
- Vol. 6 (3) , 296-302
Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel
The Asia-Pacific Journal of Ophthalmology (APJO) is the official publication of the Asia-Pacific Academy of Ophthalmology. The APJO positions itself as a first-class bimonthly (6 issues per year) peer-viewed e-journal representative of ophthalmic and visual science developments in the Asia-Pacific region. The APJO welcomes the submission of original, previously unpublished manuscripts which describe clinical investigations, clinical observations and clinically relevant laboratory investigations.
- 1 January 2017
- Published by Asia Pacific Academy of Ophthalmology in Asia-Pacific Journal of Ophthalmology
- Vol. 6 (3) , 296-302
Open AccessRecommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel
The Asia-Pacific Journal of Ophthalmology (APJO) is the official publication of the Asia-Pacific Academy of Ophthalmology. The APJO positions itself as a first-class bimonthly (6 issues per year) peer-viewed e-journal representative of ophthalmic and visual science developments in the Asia-Pacific region. The APJO welcomes the submission of original, previously unpublished manuscripts which describe clinical investigations, clinical observations and clinically relevant laboratory investigations.
- 1 April 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (4) , 686-716
POLYPOIDAL CHOROIDAL VASCULOPATHY
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy affecting vision, with clinical features distinct from neovascular age-related macular degeneration. Currently, no evidence-based guidelines exist for its diagnosis and treatment. A panel of experts analyzed a systematic literature search on PCV together with results of the EVEREST trial, the only published randomized controlled clinical trial in PCV. At a subsequent Roundtable meeting, recommendations for the management of PCV were agreed based on this analysis and their own expert opinion. Diagnosis of PCV should be based on early-phase nodular hyperfluorescence from choroidal vasculature visualized using indocyanine green angiography. Recommended initial treatment of juxtafoveal and subfoveal PCV is either indocyanine green angiography-guided verteporfin photodynamic therapy or verteporfin photodynamic therapy plus 3 × 0.5 mg ranibizumab intravitreal injections 1 month apart. If there is incomplete regression of polyps by indocyanine green angiography, eyes should be retreated with verteporfin photodynamic therapy monotherapy or verteporfin photodynamic therapy plus ranibizumab. If there is complete regression of polyps by indocyanine green angiography, but there is leakage on fluorescein angiography and other clinical or anatomical signs of disease activity, eyes should be retreated with ranibizumab. Practical guidance on the clinical management of PCV is proposed based on expert evaluation of current evidence.
- 1 April 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (4) , 686-716
POLYPOIDAL CHOROIDAL VASCULOPATHY
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy affecting vision, with clinical features distinct from neovascular age-related macular degeneration. Currently, no evidence-based guidelines exist for its diagnosis and treatment. A panel of experts analyzed a systematic literature search on PCV together with results of the EVEREST trial, the only published randomized controlled clinical trial in PCV. At a subsequent Roundtable meeting, recommendations for the management of PCV were agreed based on this analysis and their own expert opinion. Diagnosis of PCV should be based on early-phase nodular hyperfluorescence from choroidal vasculature visualized using indocyanine green angiography. Recommended initial treatment of juxtafoveal and subfoveal PCV is either indocyanine green angiography-guided verteporfin photodynamic therapy or verteporfin photodynamic therapy plus 3 × 0.5 mg ranibizumab intravitreal injections 1 month apart. If there is incomplete regression of polyps by indocyanine green angiography, eyes should be retreated with verteporfin photodynamic therapy monotherapy or verteporfin photodynamic therapy plus ranibizumab. If there is complete regression of polyps by indocyanine green angiography, but there is leakage on fluorescein angiography and other clinical or anatomical signs of disease activity, eyes should be retreated with ranibizumab. Practical guidance on the clinical management of PCV is proposed based on expert evaluation of current evidence.